Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

Funding reportedLast round: Post ipo debt

BiotechnologySouth San Francisco, United States

What company datasets say Global Blood Therapeutics raised

Funding, as reported

Reported in all$970Min dollars

Rounds7

Last roundPost ipo debt

Last round dateDec 2021

Investors listed6

SEC Form D$48M sold, 1 filing, last Jan 2015

From the SEC filings it signed: 2 on the team.

On the board, as filediCharles W. HomcyKevin W. Starr

Investors who name them

Each firm lists Global Blood Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Global Blood Therapeutics in front of investors. Or tell us what we have wrong.